Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of US ...

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Using integrated lab, claims, and EMR data, the manufacturer can pull in test results and deploy NLP on the unstructured EMR ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

In its first full year on the U.S. market, bladder cancer treatment Adstiladrin earned about $77 million. Elsewhere, Lilly ...